NuVision Biotherapies develops and manufactures amniotic-membrane–based solutions for ophthalmology. Its dual-patented Tereo Process enables scalable processing of amniotic membrane, forming the basis of its product line. The company’s first product, Omnigen, is used in operating theatres, while OmniLenz, a specialised contact lens, delivers the same therapy without surgery, extending treatment to opticians’ practices and outpatient clinics. NuVision now supplies more than 160 NHS centres and private clinics in the UK, including Moorfields Eye Hospital, and serves customers in 12 countries across Europe, Scandinavia and the Middle East. Founded by Dr. Andy Hopkinson, the company is focused on expanding operations and further product development. The newly secured capital will finance this expansion as NuVision seeks broader international reach and additional clinical applications for its technology.

Total raised

$10M

Funding rounds

4

Latest round

Equity

Latest activity

Feb 2026